Fractyl Health Announces Groundbreaking Clinical Trial Results for Revita® Procedure, Showing Sustained Weight Loss After GLP-1 Drug Discontinuation
Fractyl Health Inc. announced results from the REMAIN-1 Midpoint Cohort, a clinical study on the Revita® procedure for maintaining weight after GLP-1 drug discontinuation. Patients treated with Revita lost an additional 2.5% of body weight at three months, while the sham group regained 10% (p=0.014). The procedure showed a favorable safety profile. Upcoming milestones include six-month data in Q1 2026 and topline data from the pivotal cohort later in 2026.
Fractyl Health Inc. has announced results from the REMAIN-1 Midpoint Cohort, a clinical study evaluating the Revita® procedure for post-GLP-1 weight maintenance. The company reported that, at three months following GLP-1 drug discontinuation, patients treated with Revita lost an additional 2.5% of total body weight, while those in the sham group experienced a 10% weight regain (p=0.014). The procedure demonstrated a favorable safety and tolerability profile consistent with previous studies. These data were presented during a webcast hosted by Fractyl Health. Further milestones include delivery of six-month data from the ongoing REMAIN-1 Midpoint Cohort in the first quarter of 2026, and topline data from the pivotal cohort expected later in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535642-en) on September 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
